The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Is your patient at risk for NAFLD?
Cleve Clin J Med. 2022 Dec 1;89(12):719-727. doi: 10.3949/ccjm.89a.22005.
1Instructor of Medicine, Senior Associate Consultant, Division of Community Internal Medicine, Mayo Clinic, Scottsdale, AZ persons.patress@mayo.edu.
2Assistant Professor of Medicine, Consultant, Division of Community Internal Medicine, Mayo Clinic, Scottsdale, AZ.
3Assistant Professor of Medicine, Consultant, Division of Community Internal Medicine, Mayo Clinic, Scottdale, AZ.
Abstract
Nonalcoholic fatty liver disease (NAFLD) affects approximately 37% of US adults. The progression from nonalcoholic fatty liver with no inflammation to steatohepatitis with inflammation and progressive fibrosis is associated with substantial morbidity and mortality. The epidemic of NAFLD requires that primary care providers recognize at-risk patients and screen them. The authors review identifying individuals at risk, treatment options founded on lifestyle modification, and when to consider referring patients to a hepatologist.